Celsion Corp (CLSN)

0.39
0.00 0.78
NASDAQ : Health Care
Prev Close 0.39
Open 0.39
Day Low/High 0.34 / 0.40
52 Wk Low/High 1.04 / 2.63
Volume 1.96M
Avg Volume 431.60K
Exchange NASDAQ
Shares Outstanding 26.08M
Market Cap 10.17M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Celsion Corporation Announces Positive DSMB Review Of Phase 1b OVATION Study In Ovarian Cancer

Celsion Corporation Announces Positive DSMB Review Of Phase 1b OVATION Study In Ovarian Cancer

Study to Complete Final Patient Cohort as Planned

Celsion Corporation Announces Issuance Of Two New U.S. Patents For Its GEN-1 Immuno-Oncology Product

Celsion Corporation Announces Issuance Of Two New U.S. Patents For Its GEN-1 Immuno-Oncology Product

Strengthens Patent Portfolio around Innovative GEN-1 IL-12 Immunotherapy for the Treatment of Cancer and Hyperproliferative Diseases

Celsion Presents Data On ThermoDox® Plus Optimized RFA In Intermediate Primary Liver Cancer At The 3rd Asian Conference On Tumor Ablation (ACTA)

Celsion Presents Data On ThermoDox® Plus Optimized RFA In Intermediate Primary Liver Cancer At The 3rd Asian Conference On Tumor Ablation (ACTA)

Supportive Data for the Phase III OPTIMA Study Demonstrates the Potential for a 2 Year Overall Survival Benefit

Celsion Corporation Announces Positive DSMB Review Of Phase 1b OVATION Study In Ovarian Cancer

Celsion Corporation Announces Positive DSMB Review Of Phase 1b OVATION Study In Ovarian Cancer

Study to Continue to Fourth and Final Patient Cohort

Celsion Corporation And Zhejiang Hisun Pharmaceutical Company Sign Technology Transfer, Manufacturing And Commercial Supply Agreement For The Development Of Its GEN-1 Immuno-Oncology Therapy

Celsion Corporation And Zhejiang Hisun Pharmaceutical Company Sign Technology Transfer, Manufacturing And Commercial Supply Agreement For The Development Of Its GEN-1 Immuno-Oncology Therapy

Expanded Partnership Provides Capacity and Cost Structure Supporting Celsion's Global Commercial Strategy for GEN-1

Celsion Announces Positive Data From The OVATION Study - An Immunotherapy Study Of Newly Diagnosed Ovarian Cancer Patients

Celsion Announces Positive Data From The OVATION Study - An Immunotherapy Study Of Newly Diagnosed Ovarian Cancer Patients

Second Cohort of Stage III and IV Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1, A Novel IL-12 DNA-based Immunotherapy, in Combination with the Standard of Care

Celsion Announces Presentation Highlighting Phase III OPTIMA Study At The Asia-Pacific Primary Liver Cancer Expert Meeting

Celsion Announces Presentation Highlighting Phase III OPTIMA Study At The Asia-Pacific Primary Liver Cancer Expert Meeting

Liver Cancer Experts Endorse Pivotal Study Based On Convincing Clinical and Preclinical Data

Celsion Announces Presentation Of OVATION Study Clinical Trial Design At Upcoming ASCO 2016 Meeting

Celsion Announces Presentation Of OVATION Study Clinical Trial Design At Upcoming ASCO 2016 Meeting

Company Expects to Report Data from Second Cohort of the OVATION Study by Mid-Year, Followed by Translational Data for the First Two Cohorts in the Third Quarter

Celsion Corporation Announces Positive Data From The First Cohort Of Patients In The OVATION Study

Celsion Corporation Announces Positive Data From The First Cohort Of Patients In The OVATION Study

GEN-1 Immunotherapy Together with Standard Chemotherapy in First Line Ovarian Cancer Patients Demonstrates Impressive Outcomes

Celsion Corporation Announces Enrollment Of First Patient In The OPTIMA Study In China

Celsion Corporation Announces Enrollment Of First Patient In The OPTIMA Study In China

With China FDA's Approval of Celsion's Phase III Study in First Line Primary Liver Cancer, the Trial is Now Enrolling Patients in 13 Countries World-wide

Celsion Presents Compelling Data At AACR 2016 Demonstrating Synergistic Anti-Cancer Effect Of GEN-1 IL-12 Immunotherapy Plus Avastin® And Doxil®

Celsion Presents Compelling Data At AACR 2016 Demonstrating Synergistic Anti-Cancer Effect Of GEN-1 IL-12 Immunotherapy Plus Avastin® And Doxil®

Preclinical Studies Demonstrate a 98% Reduction in Tumor Burden Compared to Control